Last reviewed · How we verify
BACTROBAN® Nasal ong
Mupirocin is a topical antibiotic that inhibits bacterial protein synthesis by binding to isoleucyl-tRNA synthetase.
Mupirocin is a topical antibiotic that inhibits bacterial protein synthesis by binding to isoleucyl-tRNA synthetase. Used for Eradication of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA), Prevention of staphylococcal nasal colonization.
At a glance
| Generic name | BACTROBAN® Nasal ong |
|---|---|
| Sponsor | Lindenhofgruppe AG |
| Drug class | Topical antibiotic |
| Target | Isoleucyl-tRNA synthetase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Mupirocin works by inhibiting bacterial isoleucyl-tRNA synthetase, an enzyme essential for bacterial protein synthesis. This mechanism is unique among antibiotics and results in bacteriostatic activity against susceptible gram-positive bacteria, particularly Staphylococcus aureus and Streptococcus species. The nasal formulation is used to eradicate nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) and other pathogenic bacteria.
Approved indications
- Eradication of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA)
- Prevention of staphylococcal nasal colonization
Common side effects
- Nasal irritation
- Headache
- Rhinitis
- Taste perversion
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BACTROBAN® Nasal ong CI brief — competitive landscape report
- BACTROBAN® Nasal ong updates RSS · CI watch RSS
- Lindenhofgruppe AG portfolio CI